v3.25.2
Notes to the interim condensed consolidated statement of financial position - Investment in Hepalys accounted for using equity method of accounting (Details) - EUR (€)
 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Investments accounted for using the equity method        
Intangible assets € 85,000   € 48,000  
Other current assets 38,808,000   9,476,000  
Cash and cash equivalents 122,076,000 € 10,147,000 96,564,000 € 26,918,000
Total assets 178,955,000   118,967,000  
Capital stock 1,391,512.74   957,000  
Net loss for the period (175,882,000)   (184,212,000)  
Shareholders' equity (8,909,000) (79,060,000) (106,647,000) (32,032,000)
Total non-current liabilities 129,406,000   104,883,000  
Trade payables 34,703,000   32,862,000  
Other current liabilities 15,170,000   8,600,000  
Total current liabilities 58,458,000   120,731,000  
Total equity and liabilities 178,955,000   118,967,000  
Balance at the beginning (106,647,000) (32,032,000) (32,032,000)  
Net loss for the period (175,882,000) (49,029,000)    
Other comprehensive income (167,000) (146,000)    
Balance at the end (8,909,000) € (79,060,000) (106,647,000)  
Carrying amount € 835,000   € 1,139,000  
Hepalys Pharma, Inc        
Investments accounted for using the equity method        
Group's share in % 15.00% 15.00% 15.00%  
Group's share € 2,289,000   € 2,707,000  
Elimination of unrealized profit on downstream sales (1,491,000)   (1,604,000)  
Goodwill 37,000   37,000  
Carrying amount 835,000   1,139,000  
Hepalys Pharma, Inc        
Investments accounted for using the equity method        
Intangible assets 15,071,000   16,984,000  
Total non-current assets 15,071,000   16,984,000  
Other current assets 136,000   81,000  
Cash and cash equivalents 699,000   1,785,000  
Total current assets 836,000   1,866,000  
Deferred assets     2,000  
Total assets 15,907,000   18,851,000  
Capital stock 532,000   552,000  
Capital reserve 19,374,000   21,489,000  
Capital surplus-others 786,000   816,000  
earnings brought forward (2,987,000)   (1,073,000)  
Net loss for the period (2,068,000)   (3,293,000)  
Shareholders' equity 15,637,000   18,368,000 € 21,122,000
Trade payables 270,000   353,000  
Other current liabilities 0   8,000  
Total current liabilities 270,000   361,000  
Total equity and liabilities 15,907,000   18,851,000  
Balance at the beginning 18,368,000 € 21,122,000 21,122,000  
Net loss for the period (2,158,000) € (1,509,000) (3,277,000)  
Other comprehensive income (573,000)   (920,000)  
Capital variations     1,566,000  
Balance at the end 15,637,000   18,368,000  
Hepalys Pharma, Inc | Previously stated        
Investments accounted for using the equity method        
Shareholders' equity     18,490,000  
Balance at the beginning € 18,490,000      
Balance at the end     € 18,490,000